#Decitabine

[creativeera]

The Evolution of MDS Treatment: A Cross-Regional Examination of Advances in the U.S., Europe, and China

Myelodysplastic Syndrome (MDS) represents a diverse group of bone marrow disorders characterized by ineffective blood cell production and an increased risk of leukemia. As research and technology advance, treatment approaches for MDS have evolved significantly, reflecting regional differences in healthcare systems, available therapies, and patient needs. This blog explores the evolution of MDS treatment across the U.S., Europe, and China, highlighting key advancements and regional approaches that are shaping the future of care for this complex condition.

The Evolution of MDS Treatment: A Global Overview

The management of MDS has seen remarkable progress over the past few decades. Initially, treatment options were limited to supportive care and basic chemotherapy. However, the landscape has transformed with the development of targeted therapies, advancements in genetic understanding, and improved supportive care strategies. Understanding how these advancements are applied across different regions provides insight into the global approach to managing MDS.

Advances in the U.S.

In the United States, the approach to treating MDS has evolved through a combination of cutting-edge research, personalized medicine, and a focus on patient-centered care.

1. Personalized Risk Stratification

One of the most significant advancements in the U.S. has been the development of risk stratification systems such as the International Prognostic Scoring System (IPSS) and its updated versions. These tools categorize patients based on factors like genetic mutations, blood cell counts, and chromosomal abnormalities, guiding treatment decisions. The move towards personalized treatment plans allows for more tailored therapies, improving patient outcomes and minimizing unnecessary side effects.

2. Hypomethylating Agents

The introduction of hypomethylating agents, such as azacitidine and decitabine, has been a game-changer in U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment. These drugs work by modifying DNA methylation patterns, which can lead to improved blood cell production and reduced disease progression. They are now a standard treatment for patients with intermediate to high-risk MDS, offering a significant improvement over traditional chemotherapy.

3. Targeted Therapies and Clinical Trials

The U.S. is at the forefront of developing and testing new therapies through extensive clinical trials. Advances in genetic research have led to the identification of specific mutations that drive MDS, resulting in targeted therapies designed to address these genetic abnormalities. For example, drugs like lenalidomide are used for patients with deletion 5q, a specific genetic abnormality associated with MDS.

4. Stem Cell Transplantation

Allogeneic stem cell transplantation remains one of the most promising treatment options for high-risk MDS patients. The U.S. has developed sophisticated transplantation techniques and supportive care measures to improve patient outcomes and reduce complications associated with the procedure. However, due to the high risk and complexity of stem cell transplants, this option is generally reserved for younger, healthier patients.

Advances in Europe

In Europe, the treatment of MDS has evolved with a focus on standardized guidelines, integration of new research, and access to innovative therapies. The European approach emphasizes both risk-based treatment and inclusion in clinical trials.

1. European LeukemiaNet (ELN) Guidelines

The ELN provides comprehensive guidelines for the diagnosis and treatment of MDS, which are widely adopted across European countries. These guidelines incorporate risk stratification tools similar to those used in the U.S. and offer a framework for managing MDS based on the latest research and clinical evidence.

2. Access to New Therapies

European countries have been proactive in incorporating new therapies into clinical practice. For example, hypomethylating agents and targeted therapies are widely used in Europe, with many countries following similar protocols to those in the U.S. However, variations in drug availability and healthcare policies can impact the accessibility of these treatments.

3. Clinical Trials and Research

Europe is known for its robust clinical trial network, which provides patients with access to innovative treatments that may not yet be available elsewhere. European researchers are also involved in international collaborations, contributing to the global understanding of MDS and the development of new therapies.

4. Supportive Care and Palliative Options

European healthcare systems place a strong emphasis on supportive care and palliative options for MDS patients. This includes a focus on managing symptoms, improving quality of life, and providing psychological support. This approach ensures that patients receive comprehensive care, addressing both the physical and emotional aspects of living with MDS.

Advances in China

China's approach to treating MDS reflects a blend of traditional practices and modern medical advancements. The rapid development of healthcare infrastructure and increasing investment in medical research are driving significant changes in MDS treatment in the region.

1. Improved Diagnosis and Access to Care

China has made strides in improving the diagnosis of MDS through enhanced awareness and better access to diagnostic tools. Efforts to increase awareness and improve early detection are critical in a country with a large and diverse population.

2. Integration of Western Medicine and Traditional Chinese Medicine (TCM)

In China, there is a growing interest in combining Western medical treatments with Traditional Chinese Medicine (TCM). Some patients use TCM practices such as herbal remedies and acupuncture alongside conventional therapies to manage symptoms and improve overall well-being. While TCM is not considered a cure for MDS, it offers complementary benefits that can enhance the patient’s quality of life.

3. Access to Modern Therapies

China has seen improvements in access to modern treatments like hypomethylating agents and targeted therapies. The availability of these drugs can vary depending on the region, but overall, there has been progress in making these advanced treatments more accessible to patients.

4. Stem Cell Transplantation and Research

China has a large stem cell donor registry and has made significant advancements in stem cell transplantation. This procedure is increasingly available to MDS patients, particularly those with high-risk disease. Additionally, China’s investment in research is contributing to the development of new therapies and treatment strategies for MDS.

Common Challenges and Future Directions

Despite advancements in MDS treatment across the U.S., Europe, and China, there are common challenges that need to be addressed globally:

Access to Care: Disparities in access to advanced treatments and supportive care remain a challenge, particularly in low-resource settings or rural areas. Efforts to improve access and equity in healthcare are essential for ensuring that all patients receive the care they need.

Cost of Treatments: The high cost of modern therapies, including hypomethylating agents and stem cell transplantation, can be a barrier to treatment for some patients. Addressing the cost of care and exploring ways to make treatments more affordable are important considerations.

Research and Innovation: Continued investment in research is crucial for developing new therapies and improving treatment outcomes. International collaboration and sharing of research findings can accelerate progress and lead to more effective treatments for MDS.

The treatment of Myelodysplastic Syndrome (MDS) has evolved significantly, with advancements driven by research, innovation, and regional healthcare practices. The U.S., Europe, and China each contribute unique approaches to managing MDS, reflecting their distinct healthcare systems and patient needs. As global research and collaboration continue to advance, the future of MDS treatment looks promising, with new therapies and strategies on the horizon. By learning from each region’s experiences and addressing common challenges, the global medical community can work towards improving outcomes and quality of life for individuals living with MDS.

Get more insights on U.S., Europe, And China Myelodysplastic Syndrome (MDS) Treatment

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

[adoctorx]

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute myeloid leukemia (AML) is a blood cancer that causes your bone marrow to produce abnormal platelets and blood cells. It’s the most common form of acute (quickly developing) leukemia in adults and requires prompt treatment. Several treatment options for AML are available. Your treatment team will carefully consider the type of AML you have, whether the cancer has spread, and other factors when deciding your best treatment options. Medications are typically the first-line treatment. Keep reading to learn more about the medications doctors use to treat AML, including chemotherapy drugs and targeted therapies. Chemotherapy for acute myeloid leukemia Chemotherapy (“chemo”) is a class of drugs that works by either killing cancer cells directly or damaging them to a point where they stop dividing and creating new cancerous cells. While effective, chemo is also known to cause side effects, such as hair loss, nausea, and infections. Experts estimate that 2 out of 3 people with newly diagnosed AML who receive chemo as an induction therapy enter remission after treatment. Options often used in the systemic treatment of AML include: azacitidine (Onureg, Vidaza) cytosine arabinoside (cytarabine) daunorubicin (Cerubidine) decitabine (Dacogen) idarubicin (Idamycin) mitoxantrone (Novantrone) methotrexate (Trexall, Xatmep) for combination therapy only In some cases, doctors may also consider combination drugs, such as: daunorubicin and cytarabine liposome (Vyxeos) cytarabine and methotrexate The way healthcare professionals administer chemotherapy for AML depends on whether the cancer has spread to your central nervous system (CNS). If it has, they inject chemo directly into the cerebrospinal fluid, the fluid around your brain and spinal cord. This process is also called intrathecal chemotherapy. If the cancer has not spread to the CNS, a doctor might recommend systemic chemo instead. This is administered by mouth or as an injection. Sometimes, doctors may combine chemo with a stem cell transplant to help ensure the creation of new, healthy blood cells that these cancer drugs might otherwise destroy. Targeted therapy for acute myeloid leukemia Targeted therapies are among the most widely researched treatment options for AML because they can target specific genes and their proteins that contribute to cancer growth. These drugs can also cause side effects, though they range in severity and incidence between individuals. Skin changes are the most common, with other possibilities including infections, swelling, and more. Before administering these drugs, your oncologist will test to see if you have a genetic mutation. Doctors may use the following targeted therapy at the same time as, or in place of, chemo for AML: FLT3 inhibitors FLT3 inhibitors target mutations in the FLT3 gene, which can sometimes contribute to cancer. Examples include: gilteritinib (Xospata) quizartinib (Vanflyta) midostaurin (Rydapt) You would usually take these 1 to 2 times daily. IDH inhibitors IDH inhibitors block excess proteins related to genetic mutations affecting the IDH1 or IDH2 genes. Unlike other targeted therapies, IDH inhibitors can directly help immature leukemia blood cells transition into typical, healthy ones. IDH inhibitors currently approved to treat AML include: enasidenib (Idhifa) ivosidenib (Tibsovo) olutasidenib (Rezlidhia) You take these by mouth 1 to 2 times per day. BCL-2 inhibitors BCL-2 inhibitors target cellular proteins of the same name. Doctors most often prescribe these drugs for adults over age 75 who receive an AML diagnosis for the first time. Currently, the only approved BCL-2 inhibitor for AML treatment is venetoclax (Venclexta).

You take this drug by mouth once daily. Hedgehog pathway inhibitors Like BCL-2 inhibitors, doctors most commonly prescribe hedgehog pathway inhibitors for people ages 75 or older. The hedgehog signaling pathway is a key part of cell differentiation, the process in which a stem cell becomes a specific type of cell. Overactivation of this pathway can lead to some cancers, like leukemia. Currently, the only approved treatment for AML in this class is glasdegib (Daurismo). It’s not recommended for people who are or could become pregnant. You also take these pills daily. Monoclonal antibodies Monoclonal antibodies target cells with the help of lab-created proteins. While numerous monoclonal antibodies address a variety of illnesses and chronic conditions, only one is currently approved for AML: gemtuzumab ozogamicin (Mylotarg). Mylotarg works by attaching to CD33 proteins inside AML cells. It can work alongside chemotherapy by making it more effective. Unlike other targeted therapies for AML, healthcare professionals administer Mylotarg intravenously (by IV). Medications for acute promyelocytic leukemia (APL) APL is an aggressive subtype of AML. To help quickly stop this type of leukemia from progressing further, a healthcare professional may recommend the following cancer medications: All trans-retinoid acid (ATRA) ATRA is a substance derived from vitamin A. ATRA may treat APL by potentially killing cancer cells and preventing them from dividing and growing. You take this drug by mouth. Arsenic trioxide (ATO) ATO treatment (Trisenox) is an injectable medication doctors may recommend in cases of APL where the PML-RARA gene is involved. It works by destroying proteins on the gene that can subsequently help destroy leukemia cancer cells. Doctors may recommend Trisenox for APL that hasn’t improved or if the cancer has returned after using other AML treatment methods. Frequently asked questions What’s the drug of choice in acute myeloid leukemia? The best AML drug of choice depends on several factors, such as your age and overall health, whether the cancer has progressed, and whether you’ve previously undergone treatment and are experiencing a relapse. What is the new drug treatment for acute myeloid leukemia? Quizartinib (Vanflyta) is the most recent drug approved for AML treatment, having received approval from the Food and Drug Administration (FDA) in July 2023. It’s an FLT3 inhibitor, a type of targeted therapy. Researchers continue to look into new targeted therapies and immunotherapies as potential AML treatments. Menin inhibitors are among the newest classes showing promise. What is the survival rate for acute myeloid leukemia? The 5-year relative survival rate for AML was 31.9% between 2014 and 2020. This means 31.9% of people were alive 5 years after diagnosis. Factors that affect survival rate include AML that has spread to the CNS, older age, and a white blood cell count higher than 100,000 per microliter of blood when diagnosed. Takeaway AML is an aggressive type of leukemia, especially if it’s not treated quickly. Many treatments are available for this cancer, with new therapies continually under research. Talk with a healthcare professional about your medication options to determine how they might fit into your overall AML treatment plan.

[sisiad]

Genome-wide CRISPR/Cas9 library screening identified OGDH as a regulator of disease progress and resistance to decitabine in myelodysplastic neoplasm by reprogramming glutamine metabolism

http://dlvr.it/TCllLT

[healthcarehubhh]

Advancement in Healthcare Industry: Myelodysplastic Syndrome Treatment Options

Myelodysplastic syndromes are a group of hematopoietic stem cell malignancies characterized by inefficient production of blood cells. The specific treatments for MDS are tailored based on the severity and subtype of disease, as well as the patient's overall health and preferences. A few options can be considered for managing MDS. Myelodysplastic Syndrome Treatment: Bone Marrow Transplantation Bone marrow transplantation, also known as hematopoietic stem cell transplantation, is the only potential cure for MDS. It involves destroying the abnormal bone marrow using high-dose chemotherapy and replacing it with healthy stem cells from another person, usually a relative or unrelated donor. Blood stem cells can also be collected from the donor's bloodstream. Candidates must be in relatively good health and have a matched donor. Due to donor availability and transplant-related risks, it is only considered for certain subtypes and higher-risk cases. Myelodysplastic Syndrome Treatment: Drug Therapy Several drugs can be used to treat low- and intermediate-risk MDS. These include: - Azacitidine (Vidaza) and decitabine (Dacogen): These are DNA methyltransferase inhibitors that help restore normal blood cell production. They are recommended as initial therapy for most intermediate-risk and selected low-risk MDS cases. - Lenalidomide (Revlimid): An immunomodulatory drug, lenalidomide alone or with azacitidine can benefit those with chromosome 5q deletions or ring sideroblasts. - Erythropoietin-stimulating agents: Drugs like epoetin alfa and darbepoetin alfa may improve anemia in low-risk cases with ring sideroblasts or specific chromosome abnormalities. - Immunosuppressive drugs: Cyclosporine and antithymocyte globulin can be tried in syndromes associated with previous cytopenias or medications. Myelodysplastic Syndrome Treatment: Supportive Care When a patient is not a transplant candidate or has lower-risk disease, supportive care focuses on managing complications through: - Blood transfusions: Regular red blood cell and platelet transfusions help control anemia and bleeding risks. - Antibiotics: Infection prophylaxis with antibiotics is commonly used due to impaired immunity from low white blood cell counts. - Growth factors: Granulocyte colony-stimulating factors may be prescribed to boost white cell production during infection recovery. Clinical Trials Clinical trials investigate new drug therapies and treatment strategies. Eligible patients should consider enrolling in trials exploring additional treatment options. Some promising MDS therapies in trials include: - Hypomethylating agents combined with lenalidomide or immune checkpoint inhibitors - Bcl-2 inhibitors targeting MDS stem cells - Monoclonal antibodies blocking cellular targets involved in leukemia development - Next-generation epigenetic drugs with novel mechanisms of action Careful monitoring under a hematologist is imperative for ongoing care, managing side effects from any treatment received, and determining if intervention is needed due to disease progression or complications. The optimal approach aims to improve blood counts and quality of life while minimizing risks.

[arkon-solution]

Unlocking the Potential of Venclexta: A Comprehensive Guide on its Use, Latest Results, and Approval Timelines

Venclexta (venetoclax) has emerged as a promising targeted therapy for various types of cancer, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML). In this blog post, we will delve into the use of Venclexta, highlight the latest results, and discuss its approval timelines, providing an all-encompassing guide for patients, caregivers, and healthcare professionals.

Understanding the Mechanism and Use of Venclexta

Venclexta belongs to a class of medications known as BCL-2 inhibitors. By inhibiting the B-cell lymphoma 2 (BCL-2) protein, Venclexta helps to promote cancer cell death and prevent their survival. The FDA has approved the use of Venclexta in various scenarios:

Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Venclexta received initial approval for the treatment of CLL patients with a specific genetic abnormality known as the 17p deletion. It offers a much-needed treatment option for those with a high-risk genetic profile.

Small Lymphocytic Lymphoma (SLL): As SLL is closely related to CLL, Venclexta has also been approved for the treatment of SLL. It provides a valuable therapeutic option for patients with this type of lymphoma.

Acute Myeloid Leukemia (AML): More recently, Venclexta has been approved in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed AML in elderly patients or those with comorbidities that prevent the use of intensive chemotherapy. This approval showcases its potential as a novel therapy for AML patients.

Exploring the Latest Results with Venclexta

The effectiveness of Venclexta has been evaluated through numerous clinical trials, yielding significant results:

CLL and SLL: Clinical trials have shown that Venclexta, either as a monotherapy or in combination with other anti-cancer medications, has demonstrated high response rates and improved survival outcomes for CLL and SLL patients.

AML: Trials investigating Venclexta in combination with other agents for newly diagnosed AML patients unfit for intensive chemotherapy have shown promising results. The combination therapies exhibited higher response rates and extended overall survival rates, elevating Venclexta's potential in AML treatment.

Approval Timelines and Future Prospects

Venclexta has undergone a series of FDA approval milestones. The most recent approval, in October 2020, expanded its use in combination therapies for newly diagnosed AML patients unfit for intensive chemotherapy. It is important to note that approval timelines may change as research progresses and new findings emerge.

Looking ahead, ongoing research is exploring the use of Venclexta in various other cancer types and treatment regimens, with the aim of expanding its scope and benefiting a broader patient population.

Conclusion

Venclexta presents a significant breakthrough in the treatment of CLL, SLL, and AML, providing new avenues of hope for patients facing these challenging cancers. The targeted approach of Venclexta, coupled with its notable efficacy and promising clinical trial results, emphasizes its potential as a transformative therapy.

For the most accurate and up-to-date information on Venclexta's use, latest results, and approval timelines, it is advisable to consult healthcare professionals, official FDA resources, and reputable medical journals. By staying informed, patients, caregivers, and healthcare providers can unlock the full potential of Venclexta in the fight against cancer.

[epigen-papers]

The Effect of 5-aza,2'-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines

Pubmed: http://dlvr.it/SrNDtY

[leedsomics]

A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation

The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action. Problematically, some effective therapeutics target cancer vulnerabilities that we do not understand and have poorly defined mechanisms of anti-cancer activity. One such drug is decitabine, which is a frontline therapeutic approved for the treatment of high-risk acute myeloid leukemia (AML). Decitabine is thought to kill cancer cells selectively via inhibition of DNA methyltransferase enzymes, but the genes and mechanisms involved remain unclear. Here, we apply an integrated multiomics and CRISPR functional genomics approach to identify genes and processes associated with response to decitabine in AML cells. Our integrated multiomics approach reveals RNA dynamics are key regulators of DNA hypomethylation induced cell death. Specifically, regulation of RNA decapping, splicing and RNA methylation emerge as critical regulators of decitabine killing. Our results provide insights into the mechanisms of decitabine anti-cancer activity in treatment of AML and identify combination therapies which could potentiate decitabine anti-cancer activity. http://dlvr.it/SfPlV6

[shradhacmi]

Myelodysplastic Syndrome Treatment Market Spotlight: Enhancing Blood Disorder Care

Myelodysplastic Syndrome (MDS) is a group of disorders characterized by dysfunctional blood cell production in the bone marrow. It predominantly affects individuals over the age of 60 and can lead to serious complications such as anemia, bleeding, and susceptibility to infections. As medical science continues to evolve, advancements in the treatment of MDS have become a spotlight in the healthcare industry, aiming to enhance the care provided to patients with this blood disorder. Traditional treatments for MDS have included supportive care measures like blood transfusions and growth factors to alleviate symptoms. However, the landscape is rapidly changing with the emergence of targeted therapies. These therapies focus on addressing specific genetic mutations and cellular pathways associated with MDS, offering more precise and effective treatments. Global Myelodysplastic Syndrome (MDS) Treatment Market is estimated to be valued at US$ 3,265.6 million in 2022 and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030). Hypomethylating agents, such as azacitidine and decitabine, have shown promising results in restoring normal blood cell production by altering DNA methylation patterns. These agents can slow the progression of the disease and improve overall survival rates for some patients.

[ptmasterguide]

Decitabine

In this article, we will discuss Decitabine (Dosage Overview). So, let’s get started. Indications Decitabine is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess…

[technomoz]

Zydus gets USFDA nod to market Decitabine injection in the US

Zydus gets USFDA nod to market Decitabine injection in the US

Zydus Cadila announced Saturday that it has received final approval from the U.S. Food and Drug Administration (FDA) to market Decitabine for injection in the United States. It has received US Food and Drug Administration approval to market decitabine for injection at a strength of 50 mg/single-dose vial (USRLD: Dacogen). Decitabine is used to treat myelodysplastic syndromes, and certain types of…

[epigen-papers]

Decitabine-priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T-cell expansion in tumor models

Pubmed: http://dlvr.it/Sk865S

[doonitedin]

Zydus Cadila gets FDA's approval to market generic cancer drug in US

Zydus Cadila gets FDA’s approval to market generic cancer drug in US

Image Source : PTI FILE Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer. The drug will be manufactured at the group’s injectables manufacturing facility, the drugmaker said.   Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of cancers, in…

[venclyxto]

Venclyxto

Some forms of chronic lymphocytic leukemia, or white blood cell cancer, are treated with venetoclax (SLL; a type of cancer that begins mainly in the lymph nodes). As a first-line treatment for AML acute myeloid leukemia (cancer of the white blood cells) in adults aged 75 and older or in those with medical conditions that prevent them from receiving other chemotherapy drugs, this drug may be administered alone or in combination with obinutuzumab (Gazyva), rituximab (Rituxan), azacitidine (Vidaza), decitabine (Dacogen), or cytarabine. Venetoclax is a member of the class of medications known as B-cell lymphoma-2 (BCL-2) inhibitors. It operates by inhibiting an internal protein from supporting cancer cells in surviving. This assists in the elimination of cancerous cells.

Venclyxto's Operation

The active component of Venclyxto, venetoclax, interacts with the Bcl-2 protein. Leukemia cancer cells contain high levels of this protein, which helps the cells survive longer in the body and develop resistance to cancer treatments. Venetoclax stops Bcl-2 from doing its job, which prevents the illness from progressing while killing cancer cells.

How Do You Use Venclyxto Capsules? Venclyxto is only available with a valid prescription and should only be started and treated by a doctor with experience in cancer treatments. It is available as tablets (10, 50, and 100 mg), which should be taken once daily with food.

Starting at 20 mg daily, the dose of Venclyxto Capsules for CLL is gradually increased to 400 mg daily over the course of five weeks. The dosage is then maintained at 400 mg per day for the duration of the treatment, which is dependent on the drug it is given. As long as the drug is effective when taken by itself, Venclyxto is given. A 100 mg starting dose for AML is raised over three

What are Venclyxto's Side Effects? Anemia and a decrease in neutrophils were the two most frequent significant adverse effects. Pneumonia, sepsis (blood poisoning), urinary tract infection (infection of the structures that carry urine), neutropenia (low levels of neutrophils, a type of white blood cells) with or without fever, anemia, thrombocytopenia (low levels of blood platelets), hypokalaemia (low levels of potassium), decreased appetite, dizziness, headache, nausea, diarrhea, vomiting, and stomatitis (in the mouth) are the most frequent side effects (high blood levels of bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes).